More than 80% of children newly diagnosed with acute lymphoblastic leukaemia (ALL) are successfully treated today – an achievement deemed by Dr Michael Osborn as “one of the true success stories of modern medicine”.
Professor David Curtis has focused his research on searching for new ways to treat early T-cell precursor acute lymphoblastic leukaemia (ETP-ALL) which he describes as “a nasty type of leukaemia”.
The ability to use haploidentical donors, or half matched donors, is the most important recent development in stem cell transplantation, says world leader in transplant research, Professor David Curtis.
Adelaide man Graham Lewis had two stem-cell transplants and was left with severe graft-versus-host disease. He believes the existence of OCPs would have greatly improved his quality of life.
Ten months after his diagnosis and having failed standard treatment, George Yiannakis is the first of potentially 12 Australians to go on the international MM24 clinical trial for AL amyloidosis.
We spoke to Dr Sidiqi about his specialising field of amyloidosis.
Daratumumab (Darzalex®) could be the first ever therapy to be approved in Australia for AL amyloidosis.
Cast your mind back to 2019, and life pre-COVID. For 56-year-old Peter D'Onghia, that meant a relentless travel schedule with his job as an academic and medical journal publisher – something that led to a delay in following up on blood test results that were, as he puts it, "a little bit odd".
When Debbie McFarlane was diagnosed with the myeloproliferative neoplasm (MPN), polycythaemia vera (PV) in 2013, she didn’t realise it was a form of blood cancer.
A new monoclonal antibody, discovered by accident by Adelaide researchers, could become the world’s first effective treatment for primary myelofibrosis (MF).
